SYS-CON MEDIA Authors: Kevin Benedict, Rich Waidmann, Pat Romanski, Michael Jannery, Javier Paniza

News Feed Item

Tissue Engineering and Regeneration: Technologies and Global Markets

NEW YORK, Aug. 25, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Tissue Engineering and Regeneration: Technologies and Global Markets

http://www.reportlinker.com/p02313354/Tissue-Engineering-and-Regeneration-Technologies-and-Global-Markets.html

This BCC Research report presents an in-depth analysis of the global tissue engineering and regeneration market by technologies, materials, applications segments and regional markets. It includes comprehensive patent analysis that focuses on providing extensive technological trends across years and regions, including the U.S., Europe and Japan.

Use this report to:
- Receive an in-depth analysis of the global tissue engineering and regeneration market by technologies, materials, applications segments and regional markets.
- Receive an in-depth analysis of key companies operating in the global tissue engineering and regeneration market.
- Know the government regulations and legislations for tissue engineering and regenerative medicines.
- Identify major stakeholders, product portfolios and recent developments, and draw a competitive landscape for the market leaders.

Highlights
- The global tissue engineering and regeneration market reached $17 billion in 2013. This market is expected to grow to nearly $20.8 billion in 2014 and $56.9 billion in 2019, a
compound annual growth rate(CAGR) of 22.3%.
- The North American market reached $7.3 billion in 2013. This market is expected to grow to nearly $9 billion in 2014 and $22.8 billion in 2019, a CAGR of 20.5%.
- The Eupropean market reached nearly $6.9 billion in 2013. This market is expected to grow to nearly $8.3 billion in 2014 and $22.3 billion in 2019, a CAGR of 21.9%.

Introduction & Scope
INTRODUCTION
STUDY AND OBJECTIVE
- Define and identify key market segments and market structure in the tissue engineering and regeneration market.
- Measure and estimate the global tissue engineering and regeneration market and its market segments, including technologies, materials, applications and geographic
regions.
- Identify key market dynamics and the factors impacting the global tissue engineering and regeneration market and its sub-segments.
- Identify the trends, gaps and opportunities in each of the micromarkets.
- Focus exclusively on geographic segmentation. Analyze trends and opportunities in the major regions: North America, Europe, Asia-Pacific and the Rest of the World
(ROW).
- Identify major stakeholders, product portfolios and recent developments, and draw a competitive landscape for the market leaders.

SCOPE OF THE REPORT
This research report presents an in-depth analysis of the global tissue engineering and regeneration market by technologies, materials, applications segments and regional
markets. It includes key technologies involved in stem cell therapies and cell therapies. It analyzes the clinical trials and patents conducted in respective geographies. The
report is an in-depth analysis of key companies operating in the global tissue engineering and regeneration market. It includes in-depth patent analysis that focuses
on providing extensive technological trends across years and across regions, including the U.S., Europe and Japan.

The tissue engineering and regeneration market is mainly segmented into three classes: synthetic, genetically modified and biological materials. Synthetic materials
are further categorized into biodegradable synthetic polymers, scaffold (medical poly lactic acid), artificial vascular graft materials and hydrogeltechnology. The biologically
derived materials are segmented into, xenogenic tissue and collagen. The ablation device application market is further segmented on the basis of various applications for
in-depth analysis of technology markets. The market study is detailed for application based on procedures, as well as its further implication on the therapeutic area. These
two segments are also discussed in detailed for the forecast period. The market is segmented by region into the Americas, Europe, Asia-Pacific and ROW. Companies
profiled in this report include Advanced Cell Technology, Arteriocyte, Athersys, Bioheart, BioMimetic Therapeutics, BioTissue Technologies, CeraPedics, Cook Biotech,
CryoLife, Cytograft Tissue Engineering, Cytomedix, Cytori Therapeutics, Genzyme/Sanofi, Integra LifeSciences, International Stem Cell, LifeCell/Kinetic Concepts and Mesoblast.

INTENDED AUDIENCE
This report's intended audience includes:
- Tissue engineering equipment and device manufacturers and potential entrants.
- Tissue engineering and regeneration device dealers, distributors and service providers.
- Healthcare service providers and private research institutes.
- Government authorities and public service boards.
- Research institutes, associations and academics.

INFORMATION AND METHODOLOGY SOURCES
- The global tissue engineering and regeneration market was assessed and calculated via a bottom-up approach that involved identifying the market revenues of the
micromarkets that make up the macromarkets. This process was designed to ensure quality and consistency of estimates.
- In-depth primary and secondary research was conducted.
- Primary research entailed gathering intelligence from key market players. The interview participants included CEOs, key opinion leaders, product heads and
directors.
- Secondary research included the collation of data from freely available sources, as well as from paid subscriptions to specialized industry magazines and websites.
- The derived values were validated through primary research to best assure the triangulation of market estimates.
- Key factors considered during market estimations were price, volumes, incidence and prevalence rates, and the number of procedures.
- Regional segmentation was assessed through various parameters, including the number of players in a particular region, incidence and prevalence rates, the extent
of research activity occurring in that geography and future potential.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY AND OBJECTIVE 2
SCOPE OF THE REPORT 2
INTENDED AUDIENCE 3
INFORMATION AND METHODOLOGY SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 EXECUTIVE SUMMARY 6
SUMMARY TABLE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY
REGION, 2013-2019 ($ MILLIONS) 7
CHAPTER 3 TISSUE ENGINEERING AND REGENERATION 10
MARKET OVERVIEW 10
PROGRESS AND PROMISES FOR THE TISSUE ENGINEERING INDUSTRY 11
FIGURE 1 TISSUE-ENGINEERING STRATEGIES 12
REPLACING BODY PARTS THROUGH TISSUE ENGINEERING 13
NANOTECHNOLOGY FOR TISSUE REGENERATION 13
FIGURE 2 POTENTIAL NANOTECHNOLOGY APPLICATIONS 14
EFFECTS OF NANOTECHNOLOGY ON STEM CELL BEHAVIOUR FOR TISSUE
REGENERATION 14
Nanoparticles 14
Nanoscaffolds 15
NANOTECHNOLOGY IN TISSUE REGENERATION APPLICATIONS 15
Bone and Cartilage Regeneration 15
Vascular Tissue Regeneration 15
Neural Tissue Regeneration 15
GENE THERAPIES AS PART OF THE FUTURE OF TISSUE ENGINEERING 16
PROGRESS 16
PROSPECTS 17
STEM CELL TECHNOLOGIES BOON TO TISSUE ENGINEERING 17
GOVERNMENT REGULATIONS AND LEGISLATIONS 18
U.S. AND EUROPEAN REGULATION FOR TISSUE ENGINEERING PRODUCTS 18
CHINESE REGULATION FOR TISSUE ENGINEERING 19
REGULATORY DIFFERENCES 20
TABLE 1 REGULATORY APPROVAL DIFFERENCES BETWEEN THE U.S. AND EUROPE 21
ETHICAL ISSUES REGARDING STEM CELL THERAPIES AND CORD BLOOD
BANKING 21
Ethical Issues Regarding Cord Blood Banking 21
Ethical Issues in Cord Blood Stem Cell Therapies 22
IMPACT OF THE HEALTHCARE SYSTEM ON TISSUE ENGINEERING MARKET
DEVELOPMENT 22
TABLE 2 HEALTHCARE PROVISIONS BY COUNTRY, 2014 23
PORTER'S FIVE FORCE ANALYSIS OF THE TISSUE ENGINEERING AND
REGENERATION MARKET 24
FIGURE 3 PORTER'S FIVE FORCE MODEL FOR TISSUE ENGINEERING PRODUCTS 24
SUPPLIER BARGAINING POWER: MODERATE 24
BUYER BARGAINING POWER: LOW 25
THREATS FROM SUBSTITUTE PRODUCTS: LOW 25
THREATS FROM NEW ENTRANTS: HIGH 25
COMPETETION FROM INDUSTRY PLAYERS: HIGH 25
CLINICAL TRIALS 26
U.S. TISSUE ENGINEERING CLINICAL TRIALS 26
TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING 26
Completed Clinical Trials for Tissue Engineering 27
TABLE 4 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING 27
Conclusion 28
Terminated Clinical Trials for Tissue Engineering 29
TABLE 5 U.S. TERMINATED CLINICAL TRIALS 29
Conclusion 29
EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING 29
TABLE 6 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING 30
Conclusion 30
MARKET DYNAMICS 31
DRIVERS 31
Emergence of Stem Cell Technology 31
FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, 2008-2012
(NO. OF TRIALS AND TREATMENTS) 31
Prominent Potential of Nanotechnology 32
Rise in Prevalence of Trauma Emergencies and Chronic Diseases 33
TABLE 7 U.S. UNINTENTIONAL INJURIES FACTS, 2013 (NO./%) 33
Advancement in Surgical Technologies and Monitoring Devices 33
TABLE 8 REGENERATIVE MEDICINE INDUSTRY TRENDS, 2007–2011 34
RESTRAINTS 34
Operational Inefficiency 34
Stringent Regulatory Policies and Ethical Issues 35
High Treatment Cost 35
STEM CELL APPLICATION OPPORTUNITIES 35
Classification of Stem Cells According to Their Ability to Differentiate 36
Getting Core Competency in Emerging Economies 36
CHAPTER 4 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY
TECHNOLOGY 38
TABLE 9 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY
TECHNOLOGY, THROUGH 2019 ($ MILLIONS) 38
STEM CELL TECHNOLOGIES 38
TABLE 10 GLOBAL STEM CELL TISSUE ENGINEERING AND REGENERATION MARKET
BY REGION, THROUGH 2019 ($ MILLIONS) 40
STEM CELL SOURCES 40
STEM CELL EXTRACTION TECHNIQUES 41
ALTERED NUCLEAR TRANSFER 42
BLASTOMERE EXTRACTION 42
STEM CELL EXPANSION 42
STEM CELL DELIVERY 43
TABLE 11 COMMONLY USED VEHICLES FOR STEM CELL DELIVERY 44
Direct Surgical Intramyocardial Injection 44
EXISTING AND DEVELOPMENT-STAGE STEM CELL PRODUCTS 44
TABLE 12 COMMERCIALIZED TISSUE ENGINEERING PRODUCT SALES, 2011 ($
MILLIONS) 45
Clinical Application of Stem Cell Technologies in the Commercial
Market 45
Cardiovascular Repair 45
Neural Repair 45
Bone Repair 46
Skeletal Muscle Repair 46
Urologic Repair 46
CELL CULTURE TECHNOLOGIES 46
PROJECT NO. 1 48
Project Description 48
PROJECT NO. 2 48
Project Description 48
PROJECT NO. 3 49
Project Description 49
PROJECT NO. 4 49
Project Description 49
PROJECT NO. 5 49
Project Description 49
PROJECT NO. 6 50
Project Description 50
PROJECT NO. 7 50
Project Description 50
TABLE 13 GLOBAL CELL CULTURE TISSUE ENGINEERING AND REGENERATION
MARKET BY REGION, THROUGH 2019 ($ MILLIONS) 51
IMMUNOPASSIVATION AND IMMUNOMODULATION 51
IMMUNOMODULATION 51
CELL ENCAPSULATION 52
TABLE 14 GLOBAL IMMUNOPASSIVATION AND IMMUNOMODULATION TISSUE
ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($
MILLIONS)
53
CHAPTER 5 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY
MATERIALS 55
TABLE 15 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY
MATERIAL, THROUGH 2019 ($ MILLIONS) 55
SYNTHETIC MATERIALS 55
TABLE 16 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION
MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS) 56
TABLE 17 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION
MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS) 56
BIODEGRADABLE SYNTHETIC POLYMERS 56
TABLE 18 BIODEGRADABLE POLYMER CLASSIFICATION 57
TABLE 19 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MATERIAL MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 58
MEDICAL POLY LACTIC ACID SCAFFOLD 58
TABLE 20 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS 59
TABLE 21 GLOBAL SCAFFOLD MATERIAL MARKET BY REGION, THROUGH 2019 ($
MILLIONS) 60
ARTIFICIAL VASCULAR GRAFT MATERIALS 60
Stem Cell Integration in Vascular Tissue Engineering 60
Extracellular Matrix ECM-Based Vascular Grafts 60
Cell Sheets without Scaffold Support 61
TABLE 22 GLOBAL ARTIFICIAL VASCULAR GRAFT MATERIAL MARKET BY REGION,
THROUGH 2019 ($ MILLIONS) 61
HYDROGEL TECHNOLOGY 61
TABLE 23 GLOBAL HYDROGEL TECHNOLOGY MARKET BY REGION, THROUGH 2019
($ MILLIONS) 62
BIOLOGICALLY DERIVED MATERIALS 62
TABLE 24 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND
REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS) 63
TABLE 25 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND
REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS) 63
COLLAGEN 63
TABLE 26 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET
BYREGION, THROUGH 2019 ($ MILLIONS) 64
TABLE 27 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 64
Animal-Derived 65
Recombinant 65
XENOGENIC TISSUE 65
TABLE 28 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MATERIAL MARKET
BY REGION, THROUGH 2019 ($ MILLIONS) 66
GENETICALLY ENGINEERED MATERIALS 66
TABLE 29 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY TYPE,
THROUGH 2019 ($ MILLIONS) 66
TABLE 30 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY REGION,
THROUGH 2019 ($ MILLIONS) 66
DEOXYRIBONUCLEIC ACID TRANSFECTION VECTORS 67
TABLE 31 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 68
GENETICALLY MANIPULATED CELLS 68
TABLE 32 GLOBAL GENETICALLY MANIPULATED CELL MARKET BY REGION,
THROUGH 2019 ($ MILLIONS) 69
THREE-DIMENSIONAL POLYMER TECHNOLOGY 69
TABLE 33 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 70
TRANGENICS 70
TABLE 34 GLOBAL TRANSGENIC TECHNOLOGY MARKET BY REGION, THROUGH
2019 ($ MILLIONS) 70
FIBROBLASTS 71
TABLE 35 GLOBAL FIBROBLAST MARKET BY REGION, THROUGH 2019 ($ MILLIONS) 71
NEURAL STEM CELLS 71
TABLE 36 GLOBAL NEURAL STEM CELL MARKET BY REGION, THROUGH 2019 ($
MILLIONS) 72
GENE-ACTIVATED MATRICES 72
TABLE 37 GLOBAL GENE-ACTIVATED MATRIX MARKET BY REGION, THROUGH 2019
($ MILLIONS) 73
CHAPTER 6 TISSUE ENGINEERING AND REGENERATION MARKET BY APPLICATION 75
TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION APPLICATION
MARKET BY TYPE, THROUGH 2019 ($ MILLIONS) 75
INTERNAL ORGAN REGENERATION 75
TABLE 39 GLOBAL INTERNAL ORGAN REGENERATION APPLICATION MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 76
LIVER REGENERATION 76
TABLE 40 U.S. LIVER FAILURE STATISTICS, 2011 77
TABLE 41 ARTIFICIAL LIVER SUPPORT SYSTEMS 78
PANCREAS AND ISLET CELL REGENERATION 79
TABLE 42 U.S. PANCREATIC CANCER AND DIABETES STATISTICS, 2010 79
KIDNEY AND RENAL TUBULE REGENERATION 81
TABLE 43 U.S. KIDNEY DISEASE STATISTICS, 2010 82
ORTHOPEDIC APPLICATIONS 82
TABLE 44 KEY FACTS REGARDING ORTHOPEDIC DISEASES, BY REGION 82
TABLE 45 GLOBAL ORTHOPEDIC APPLICATION MARKET BY REGION, THROUGH
2019 ($ MILLIONS) 83
BONE REPAIR AND REPLACEMENT 83
TABLE 46 BONE DAMAGE AND RELATED DISEASES, 2011 (MILLIONS) 84
CARTILAGE AND CONNECTIVE TISSUE DAMAGE TREATMENT 84
TISSUE-ENGINEERED PRODUCTS FOR BONE DEFECTS 85
CARTILAGE REPAIR AND REPLACEMENT 87
TABLE 47 GLOBAL CARTILAGE DAMAGE STATISTICS, 2007 87
MENISCUS REPAIR AND REPLACEMENT 88
TENDON AND LIGAMENT REPAIR AND REPLACEMENT 88
TISSUE ENGINEERING FOR THE CENTRAL NERVOUS SYSTEM 89
TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM DISEASES 90
TABLE 48 GLOBAL TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM
APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS) 91
NEUROSURGICAL 91
Cell Implants for Parkinson's Diseases 92
TABLE 49 GLOBAL NEURODEGENERATIVE DISEASE STATISTICS, 2011 93
Cell Transplants for Epilepsy Treatment 93
Stem Cell Therapy for Multiple Sclerosis 93
SPINAL CORD INJURY AND SPINAL DISC REPAIR AND REPLACEMENT 94
TABLE 50 GLOBAL SPINAL CORD INJURY STATISTICS, 2011 94
Spinal Cord Injury Treatments 94
Tissue Engineering for Spinal Cord Injury 95
Cell Therapy for Spinal Cord Injury 95
Scaffold Approach for Spinal Cord Injury Treatment 96
TISSUE ENGINEERING FOR CARDIOVASCULAR DISORDERS 97
TABLE 51 GLOBAL CARDIOVASCULAR DISORDERS APPLICATION MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 98
PERIPHERAL VASCULAR DISEASE APPLICATIONS 98
CORONARY ARTERY DISEASE APPLICATIONS 99
Heart Valves and Tissue Engineering 100
Mechanical Heart Valves 100
Biological Heart Valves 100
TABLE 52 COMPANIES DEVELOPING CELL THERAPIES FOR CARDIO VASCULAR
DISORDERS, 2013 101
DENTAL TISSUE ENGINEERING 102
TABLE 53 GLOBAL DENTAL TISSUE ENGINEERING APPLICATION MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 103
DERMATOLOGY TISSUE ENGINEERING 103
TABLE 54 U.S. AND GLOBAL SKIN DAMAGE MEDICAL CONDITION STATISTICS, 2011 104
TABLE 55 COMMERCIALIZED ACELLULAR SKIN TISSUE-ENGINEERED, 2014 105
TABLE 56 COMMERCIALIZED CELLULAR SKIN TISSUE ENGINEERED PRODUCTS 105
TABLE 57 GLOBAL DERMATOLOGY TISSUE ENGINEERING APPLICATION MARKET BY
REGION, THROUGH 2019 ($ MILLIONS) 107
WOUND MANAGEMENT 107
TABLE 58 WOUND CARE MARKET BY CATEGORY (%) 107
Burn Treatment 108
Ulcer Treatment 109
ANTI-AGING THERAPIES 110
OTHERS 110
TABLE 59 GLOBAL OTHER APPLICATION MARKET BY REGION, THROUGH 2019 ($
MILLIONS) 110
MUSCLE REGENERATION 110
TABLE 60 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING 111
PERIPHERAL NERVE REPAIR 112
HERNIA AND SOFT TISSUE REPAIR 112
CHAPTER 7 TISSUE ENGINEERING AND REGENERATION MARKET BY REGION 114
TABLE 61 COMPANIES OPERATING IN REGENERATIVE MEDICINES MARKET BY
CONTINENT, 2011 ($ MILLIONS) 114
TABLE 62 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION,
THROUGH 2019 ($ MILLIONS) 114
NORTH AMERICA 115
TABLE 63 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS,
2013 115
TABLE 64 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION
APPLICATION MARKET, THROUGH 2019 ($ MILLIONS) 119
U.S. SKIN TISSUE ENGINEERING PRODUCT MARKET 119
TABLE 65 U.S. SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, 2011 119
U.S. CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET 120
TABLE 66 U.S. BONE DAMAGE AND RELATED DISEASE STATISTICS, 2011 121
U.S. TISSUE ENGINEERING PRODUCTS FOR CARDION VASCULAR
DISORDERS MARKET 121
TABLE 67 U.S. CARDIOVASCULAR DISORDER STATISTICS, 2010 AND 2011 121
EUROPE 122
TABLE 68 TISSUE ENGINEERING FIRMS BY TYPE, 2012 (%) 122
TABLE 69 EUROPEAN TISSUE ENGINEERING FIRMS BY REGION, 2012 (%) 123
TABLE 70 EUROPEAN SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE
STATISTICS, 2011 123
TABLE 71 EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN
TISSUE-ENGINEERED PRODUCTS, 2013 124
TABLE 72 EUROPEAN TISSUE ENGINEERING AND REGENERATION APPLICATION
MARKET, THROUGH 2019 ($ MILLIONS) 125
EUROPEAN AND BONE TISSUE ENGINEERING PRODUCT MARKET 126
TABLE 73 EUROPEAN BONE DAMAGE AND RELATED DISEASE MARKET BY
COUNTRY 126
EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR
DISORDERS MARKET 126
TABLE 74 EUROPEAN CARDIOVASCULAR DISORDER STATISTICS, 2011 127
TABLE 75 EUROPEAN RATE OF DEATH FROM HEART DISEASE BY COUNTRY, 2011
(DEATHS PER 100,000 CASES) 127
EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS
SYSTEM-RELATED INJURIES AND DISORDERS MARKET 128
TABLE 76 EUROPEAN CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, 2011 129
TABLE 77 EUROPEAN SPINAL CORD INJURY AND PARKINSON'S DISEASE BY
COUNTRY, 2011 129
TABLE 78 EUROPEAN STEM CELL POLICIES BY COUNTRY, 130
TABLE 79 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE
ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS
AND INJURIES
131
EUROPEAN TISSUE ENGINEERING FOR INTERNAL ORGANS MARKET 131
ASIA-PACIFIC 132
FIGURE 5 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE 133
TABLE 80 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION APPLICATION
MARKET, THROUGH 2019 ($ MILLIONS) 134
ASIA-PACIFIC CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT
MARKET 134
ASIA-PACIFIC MARKET FOR CARDIOVASCULAR TISSUE ENGINEERING
PRODUCTS 134
ASIA-PACIFIC SKIN TISSUE ENGINEERING PRODUCT MARKET 134
REST OF THE WORLD 135
TABLE 81 GLOBAL SKIN-RELATED MEDICAL CONDITION STATISTICS, 2011 135
TABLE 82 REST OF WORLD TISSUE ENGINEERING AND REGENERATION
APPLICATION MARKET, THROUGH 2019 ($ MILLIONS) 137
REST OF THE WORLD CARTILAGE AND BONE TISSUE ENGINEERING
PRODUCT MARKET 137
REST OF WORLD TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR
DISORDERS MARKET 138
TABLE 83 GLOBAL CARDIOVASCULAR DISORDER STATISTICS, 2011 138
TABLE 84 REST OF THE WORLD COMPANIES THAT MANUFACTURE AND DEVELOP
TISSUE-ENGINEERED PRODUCTS FOR CARDIOVASCULAR DISORDER, BY COUNTRY 139
REST OF THE WORLD TISSUE ENGINEERING PRODUCTS FOR CENTRAL
NERVOUS SYSTEM-RELATED INJURIES AND DISEASES MARKET 139
TABLE 85 GLOBAL CENTRAL NERVOUS SYSTEM DISORDER AND INJURY STATISTICS,
2011 140
CHAPTER 8 COMPETITIVE LANDSCAPE 142
FIGURE 6 KEY COMPETITIVE STRATEGIES*, 2010-2014 (%) 142
TABLE 86 KEY COMPETITIVE STRATEGIES, 2010-2014 (%) 143
APPROVAL 143
FIGURE 7 APPROVAL STRATEGY BY COMPANY, 2010-2014 (%) 144
TABLE 87 APPROVAL STRATEGIES BY COMPANY, 2010-2014 (NO./%) 145
TABLE 88 KEY APPROVALS, 2010-2014 145
AGREEMENTS, MERGERS AND ACQUISITIONS 146
FIGURE 8 AGREEMENTS, MERGERS AND ACQUISITIONS, BY COMPANY, 2010-2014
(%) 147
TABLE 89 AGREEMENTS, MERGERS AND ACQUISITIONS BY COMPANY, 2010-2014
(%) 148
TABLE 90 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010-2014 148
PRODUCT LAUNCHES AND CLINICAL TRIALS 149
FIGURE 9 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%) 150
TABLE 91 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%) 151
TABLE 92 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010 AND 2014 151
CHAPTER 9 PATENT ANALYSIS 153
TABLE 93 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%) 153
FIGURE 10 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%) 153
U.S. PATENT ANALYSIS BY MARKET PARTICIPANT 154
TABLE 94 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%) 154
FIGURE 11 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%) 154
U.S. PATENT ANALYSIS BY APPLICATIONS 155
TABLE 95 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%) 155
FIGURE 12 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%) 155
EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT 156
TABLE 96 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%) 156
FIGURE 13 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%) 156
EUROPEAN PATENT ANALYSIS BY APPLICATIONS 157
TABLE 97 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%) 158
FIGURE 14 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%) 158
JAPANESE PATENT ANALYSIS BY APPLICATION 158
TABLE 98 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%) 159
FIGURE 15 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%) 159
CHAPTER 10 COMPANY PROFILES 161
ADVANCED BIOHEALING (A SHIRE PHARMACEUTICAL COMPANY) 161
TISSUE ENGINEERING PRODUCT PORTFOLIO 161
TABLE 99 ADVANCED BIOHEALING RECENT DEVELOPMENTS 162
TABLE 100 ADVANCED BIOHEALING FINANCIALS, 2011-2013 ($ MILLIONS/%) 162
ADVANCED CELL TECHNOLOGY INC. 162
TISSUE ENGINEERING PRODUCT PORTFOLIO 163
TABLE 101 ADVANCED CELL TECHNOLOGY INC. RECENT DEVELOPMENTS 163
ARTERIOCYTE 163
TISSUE ENGINEERING PRODUCT PORTFOLIO 163
TABLE 102 ARTERIOCYTE RECENT DEVELOPMENTS 164
ATHERSYS INC. 164
TISSUE ENGINEERING PRODUCT PORTFOLIO 164
TABLE 103 ATHERSYS INC. RECENT DEVELOPMENTS 165
TABLE 104 ATHERSYS FINANCIALS, 2011-2013 ($ MILLIONS/%) 165
BIOHEART INC. 165
TISSUE ENGINEERING PRODUCT PORTFOLIO 166
TABLE 105 BIOHEART INC. RECENT DEVELOPMENTS 166
CERAPEDICS INC. 166
TISSUE ENGINEERING PRODUCT PORTFOLIO 167
TABLE 106 CERAPEDICS INC. RECENT DEVELOPMENTS 167
CO.DON AG 167
TISSUE ENGINEERING PRODUCT PORTFOLIO 168
TABLE 107 CO.DON AG RECENT DEVELOPMENTS 168
COOK MEDICAL INC. 168
TISSUE ENGINEERING PRODUCT PORTFOLIO 169
TABLE 108 COOK MEDICAL INC. RECENT DEVELOPMENTS 169
CRYOLIFE INC 169
TISSUE ENGINEERING PRODUCT PORTFOLIO 169
TABLE 109 CRYO LIFE INC. RECENT DEVELOPMENTS 170
CYTOGRAFT TISSUE ENGINEERING 170
TISSUE ENGINEERING PRODUCT PORTFOLIO 170
TABLE 110 CYTOGRAFT TISSUE ENGINEERING RECENT DEVELOPMENTS 171
CYTOMEDIX INC. 171
TISSUE ENGINEERING PRODUCT PORTFOLIO 171
TABLE 111 CYTOMEDIX INC. RECENT DEVELOPMENTS 172
CYTORI THERAPEUTICS INC. 172
TISSUE ENGINEERING PRODUCT PORTFOLIO 172
TABLE 112 CYTORI THERAPEUTICS INC. RECENT DEVELOPMENTS 173
TABLE 113 CYTORI THERAPEUTICS FINANCIALS, 2011-2013 ($ MILLIONS/%) 173
GENZYME (A SANOFI COMPANY) 173
TISSUE ENGINEERING PRODUCT PORTFOLIO 174
TABLE 114 GENZYME RECENT DEVELOPMENTS 174
TABLE 115 GENZYME FINANCIALS, 2011-2013 ($ MILLIONS/%) 174
KINETIC CONCEPTS INC. 174
TISSUE ENGINEERING PRODUCT PORTFOLIO 175
TABLE 116 KINETIC CONCEPTS INC. RECENT DEVELOPMENTS 175
TABLE 117 KINETICS CONCEPTS FINANCIALS, 2011-2013 ($ MILLIONS/%) 175
MESOBLAST LTD. 176
TISSUE ENGINEERING PRODUCT PORTFOLIO 176
ORGANOGENESIS INC. 176
TISSUE ENGINEERING PRODUCT PORTFOLIO 176
ORTHOPEUTICS 177
WRIGHT MEDICAL TECHNOLOGY INC. 177
TISSUE ENGINEERING PRODUCT PORTFOLIO 177
TABLE 118 WRIGHT MEDICAL TECHNOLOGY INC. RECENT DEVELOPMENTS 178
TABLE 119 WRIGHT MEDICAL TECHNOLOGY FINANCIALS, 2011–2013 ($
MILLIONS/%) 178
CHAPTER 11 PATENTS 180
TABLE 120 NORTH AMERICAN PATENTS 180
TABLE 121 EUROPEAN PATENTS 181
TABLE 122 JAPANESE PATENTS 182



To order this report: Tissue Engineering and Regeneration: Technologies and Global Markets
http://www.reportlinker.com/p02313354/Tissue-Engineering-and-Regeneration-Technologies-and-Global-Markets.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Entuity®, a provider of enterprise-class network management solutions, today announced that it solidifies its position as a market leader through global enterprise customer acquisitions and a refined channel strategy. In 2014, Entuity increased new license revenues in EMEA by over 75 percent, and LATAM by over 125 percent as customers embraced Entuity for its highly automated solution and unified architecture. Entuity’s refined channel strategy focuses on even deeper strategic alignment with ke...
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling your Cloud initiative? In his session at DevOps Summit, Damon Edwards, co-founder and managing partner of the DTO Solutions, will highlight the successful organizational, process, and tooling patterns of high-performing c...
Technology is enabling a new approach to collecting and using data. This approach, commonly referred to as the "Internet of Things" (IoT), enables businesses to use real-time data from all sorts of things including machines, devices and sensors to make better decisions, improve customer service, and lower the risk in the creation of new revenue opportunities. In his General Session at Internet of @ThingsExpo, Dave Wagstaff, Vice President and Chief Architect at BSQUARE Corporation, discuss the ...
“We help people build clusters, in the classical sense of the cluster. We help people put a full stack on top of every single one of those machines. We do the full bare metal install," explained Greg Bruno, Vice President of Engineering and co-founder of StackIQ, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
At 15th Cloud Expo, Shrikant Pattathil, Executive Vice President at Harbinger Systems, demos a video delivery platform that helps you do interactive videos. He discusses how Harbinger is accomplishing it in the cloud world, the problems they faced and the choices they made to get around these problems.
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
AppDynamics, the application intelligence leader for software-defined businesses, announced the general availability of the AppDynamics Fall '14 Release. Serving the combined needs of IT and business teams across the enterprise, the latest release provides a comprehensive view across all aspects of digital performance in ultra large scale deployments. AppDynamics delivers Application Intelligence by building out advanced capabilities across the key areas of analytics, unified monitoring and D...
CloudBees, Inc., has announced a $23.5 million financing round, led by longtime CloudBees investor Lightspeed Venture Partners. Existing investors Matrix Partners, Verizon Ventures and Blue Cloud Ventures also participated in the round. The latest funding announcement follows earlier rounds of $4 million, $10.5 million and $10.8 million, bringing the total investment in CloudBees to just under $50 million since the company’s inception in 2010. Previous venture investment rounds were led by Ma...
In this Women in Technology Power Panel at 15th Cloud Expo, moderated by Anne Plese, Senior Consultant, Cloud Product Marketing at Verizon Enterprise, Esmeralda Swartz, CMO at MetraTech; Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems; Seema Jethani, Director of Product Management at Basho Technologies; Victoria Livschitz, CEO of Qubell Inc.; Anne Hungate, Senior Director of Software Quality at DIRECTV, discussed what path they took to find their spot within the tec...
We’re no longer looking to the future for the IoT wave. It’s no longer a distant dream but a reality that has arrived. It’s now time to make sure the industry is in alignment to meet the IoT growing pains – cooperate and collaborate as well as innovate. In his session at @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, will examine the key ingredients to IoT success and identify solutions to challenges the industry is facing. The deep industry expertise be...
The cloud is becoming the de-facto way for enterprises to leverage common infrastructure while innovating and one of the biggest obstacles facing public cloud computing is security. In his session at 15th Cloud Expo, Jeff Aliber, a global marketing executive at Verizon, discussed how the best place for web security is in the cloud. Benefits include: Functions as the first layer of defense Easy operation –CNAME change Implement an integrated solution Best architecture for addressing network-l...
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
The Industrial Internet revolution is now underway, enabled by connected machines and billions of devices that communicate and collaborate. The massive amounts of Big Data requiring real-time analysis is flooding legacy IT systems and giving way to cloud environments that can handle the unpredictable workloads. Yet many barriers remain until we can fully realize the opportunities and benefits from the convergence of machines and devices with Big Data and the cloud, including interoperability, ...